AIMS AND SCOPE

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is listed on PubMed and free-to-view/download on PubMed Central.

Aim: publishes high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas.

Scope: covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics are welcomed. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.

Peer review: single-blind peer review with comments from at least two peer reviewers – first editorial decision within 3 weeks of manuscript submission; online publication within 3 weeks of acceptance.


SUBMISSION/PUBLICATION CHARGES

Author Processing Charge (APC) for an unsolicited manuscript is $1900 / £1450 / €1680  + VAT (where applicable).
Charges are reviewed annually.

There are no additional charges. Submitting an article costs nothing.

Details

  • The Editor-in-Chief will let you know within 24 hours of submission if an article is suitable for peer review.
  • If your article is rejected at this stage, you will have nothing to pay.
  • If your article is accepted at this initial stage, it will be sent for peer review.
  • Authors will be invoiced for the article-processing charge (APC) after their manuscript has passed peer review and been accepted by the EIC. We request 14-day payment terms and reserve the right to delay releasing article data to PubMed until payment of the APC is made in full.
    • APC charges are reviewed each calendar year. The charge made for articles submitted in any given December will be the charge of the following year.
  • Waivers can be made available for developing countries. Please send an email inquiry to the Editorial Office for further information.

SPEED OF PUBLICATION

  • The Editor-in-Chief will let you know within 24 hours of submission if an article is suitable for peer review.
  • Peer review completed and first editorial decision within 3 weeks of manuscript submission
  • Final decision within 5 days of receipt of revised manuscript
  • Online publication within 3 weeks of acceptance.

Our aim is to ensure that your article is of the highest standard and is published without delay.


TYPES OF ARTICLES

  • Original research
  • Review (usually invited, but enquiries welcome)
  • Letter-to-the-Editor (this can include a letter about any contentious issue or topical debate in therapeutics)
  • Case report
  • Editorial
  • Conference report
  • Educational section: question and answer format, summary of medical information

KEY EDITORIAL FEATURES

  • Listed on PubMed
  • Rapid and rigorous peer review
  • Open access publication
  • All articles also on PubMed Central

THERAPEUTIC AREAS

Drugs in Context covers all of the main therapeutic areas, each with its own Associate Editors and a panel of Consulting Editors to cover areas such as clinical pharmacology and biostatistics. Thus, we may publish articles across all therapeutic areas as well as those relating to topics such as drug safety, pharmacoepidemiology, pharmaceutical formulations and biosimilars. For further information, please visit out Editorial Boards page http://www.drugsincontext.com/editorial-board/


ACCEPT/REJECT RATES

Drugs in Context publishes mostly invited REVIEW articles and unsolicited ORIGINAL RESEARCH manuscripts. Most authors contact the Editor-in-Chief before submission for an initial appraisal of their article. This helps both authors and the journal to make good decisions on where to publish before actual submission. This personalised approach reduces an unnecessary high rejection rate, (the ‘rejection rate’ is used by many other journals as a cavalier indication of its quality, whereas we like to think that the end product speaks for itself.

All article submissions must be within the Aims and Scope, but we do not reject articles simply because the authors report negative or ambivalent results, nor do we reject articles of questionable impact.

Since Drugs in Context became open access in May 2012, around 25% of article submissions have been rejected before peer review, mainly because the articles were outside the Aims and Scope of the journal.

All articles sent for peer review were returned to authors within 10 days of submission requiring minor and/or major revision. Of these, every article that was revised and resubmitted was published which is a testament to our philosophy of promoting constructive peer review and helping authors achieve publication.


PUBMED

Upon publication articles are indexed in PubMed, the Directory of Open Access Journals, Embase and Scopus. All articles are archived in PubMed Central, PubMed Central Canada, Europe PubMed Central and the British Library.


OPEN ACCESS STATEMENT AND COPYRIGHT POLICY

We apply either of two different copyright licenses depending upon how the article has been funded.

Publicly funded research – Creative Commons License Deed CC BY 4.0

This allows anyone including you to copy, distribute, transmit and adapt the article provided it is properly attributed in the manner specified by Drugs in Context (but not in any way that suggests that Drugs in Context endorses you or your use of the work).

Key features

  • Full text PDFs of all articles deposited in PubMed Central, Europe PubMed Central & PubMed Central Canada immediately upon publication
  • No embargoes
  • Authors retain copyright
  • Authors can self-archive and the journal would appreciate a link to the original online version of the article on the Drugs in Context website

Private or commercially funded research – Creative Commons License Deed CC BY NC ND 4.0

This allows anyone including you to copy, distribute and transmit the article provided it is properly attributed in the manner specified by Drugs in Context (but not in any way that suggests that Drugs in Context endorses you or your use of the work). The CC BY NC ND License Deed forbids the production of derivates and commercial use of articles without the express permission of the Publisher.

Key features

  • Full text PDFs of all articles deposited in PubMed Central, Europe PubMed Central & PubMed Central Canada immediately upon publication
  • No embargoes
  • Authors retain copyright
  • Authors can self-archive provided that a link is given to the original online version of the article on the Drugs in Context website.

Under this license, Drugs in Context reserves the exclusive right to market authors’ articles to commercial users worldwide and to levy fees as appropriate for their reproduction, translation and dissemination in printed and any other form. For the avoidance of doubt, under CC BY NC ND 4.0 License Deed, agreeing to our Terms and Conditions of Publication (TCP) assigns an exclusive commercial re-use rights license to the Publisher of all the material. And any commercial use or re-use of the Work without the Publisher’s written consent will be a breach of the TCP and any author or third party acting in breach of these terms will be liable to the Publisher for such an amount as the Publisher would have charged for providing permission for commercial re-use of the Work plus all legal/recovery costs. Statutory fair use and other rights are in no way affected by the above.

For further information on commercial use, please contact the Editorial Office.

 

How to correctly attribute Creative Commons articles

The copyright license for publicly funded research is Creative Commons License Deed CC BY 4.0 Example of a correct attribution:
Copyright © 2013 Schwartz TL, Goradia V. http://dx.doi.org/10.7573/dic.212259. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY 4.0.

The copyright license for privately funded research is Creative Commons License Deed CC BY NC ND 4.0. Example of a correct attribution:
© 2013 Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko NN, Gao HY. http://dx.doi.org/10.7573/dic.212260. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY NC ND 4.0.


HOW RIGOROUS IS YOUR PEER REVIEW PROCESS?

Our peer review process is very rigorous yet constructive, supportive and respectful of authors’ efforts. As a member of the Committee of Publication Ethics (COPE), we follow COPE’s Ethical Guidelines for Peer Reviewers. We urge all of our peer reviewers to adopt a positive attitude and to support authors with constructive advice and helpful suggestions.
Bioexcel Publishing Ltd does not influence the editorial decisions made by the Editor-in-Chief. The Editorial Board and any peer reviewers receive no fees to perform peer review. Instead, we encourage peer review recognition with Publons.


IS DRUGS IN CONTEXT COMPLIANT WITH THE ACCESS POLICIES OF FUNDERS OF ACADEMIC RESEARCH?

Yes, Drugs in Context is compliant with access policies of the public funders of research such as the US National Institutes of Health, The Wellcome Trust and the UK Medical Research Council. These require articles to be published under the Creative Commons License Deed CC BY 4.0 the key features of which are:

  • Full text PDFs of all articles deposited in PubMed Central, Europe PubMed Central & PubMed Central Canada immediately upon publication
  • No embargoes
  • Authors retain copyright
  • Authors can self-archive

Further information

The Wellcome Trust and the UK Medical Research Council
SHERPA Funders’ and Authors’ Compliance Tool
The US National Institutes of Health


HOW DO YOU ASSURE THE HIGHEST QUALITY EDITORIAL STANDARDS?

Editorial Board

Drugs in Context covers all of the main therapeutic areas, each with its own Associate Editors and a panel of Consulting Editors to cover areas such as clinical pharmacology and biostatistics. So whether your article is in Oncology, Cardiology, Primary Care, Endocrinology or Health Economics, there is a section of the journal dedicated to your therapeutic interest. http://www.drugsincontext.com/editorial-board

Rigorous and supportive peer review

As a member of the Committee of Publication Ethics (COPE), we follow COPE’s Ethical Guidelines for Peer Reviewers. We urge all of our peer reviewers to adopt a positive attitude and to support authors with constructive advice and helpful suggestions.

Memberships

Committee on Publication Ethics
Drugs in Context is a member of the Committee on Publication Ethics (COPE) and abides by the COPE Code of Conduct. The publisher follows what are commonly referred to as GPP2 – or the Good Publication Practice Guidelines.

The Committee of Publication Ethics provides advice to editors and publishers on all aspects of publication ethics. All COPE members are expected to follow the Code of Conduct for Journal Editors. COPE will investigate complaints that members have not followed the Code. COPE also funds research on publication ethics, publishes a quarterly newsletter and organizes annual seminars in the UK and the USA. COPE has also created an audit tool for members to measure compliance with its Code of Conduct and Best Practice Guidelines for Journal Editors.

CrossRef
CrossRef is an independent membership association and its mission is to improve access to published scholarship through services that require collective agreement among scholarly and professional publishers. CrossRef enables citation linking in journals using the Digital Object Identifier, or DOI. The CrossRef DOI is paired with the object’s electronic address, or URL, in a central DOI directory that is easily updated. The CrossRef DOI is published in place of the URL to prevent link attrition while allowing the content to move as needed.

International Committee of Medical Journal Editors (ICMJE) and GPP3
We follow the ICMJE’s recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. Drugs in Context endorses GPP3 and it is a requirement of submission for authors to confirm that their paper complies with GPP3.

Plagiarism screening on all articles
All submitted articles are screened with iThenticate software prior to further processing.

Mandatory disclosure for authors, peer reviewers and Editorial Board members

Drugs in Context is committed to transparency and the avoidance of bias at all levels of the publishing process. Therefore, authors/editors/reviewers (professional or academic, paid or unpaid) must declare all relevant competing interests for consideration during the review process by signing a formal statement of interest.

A competing interest is anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making or publication of research or non-research articles submitted. Competing interests can be financial or nonfinancial, professional or personal. Competing interests can arise from a relationship to an organization or another person.

Everyone involved in authorship, funding, review and editorial decision-making of submitted articles must declare any and all relevant competing interests.

Failure to declare competing interests at submission, or when an article is commissioned, may result in immediate rejection of the paper. If a competing interest comes to light after publication Drugs in Context will issue a formal correction or retraction of the whole paper, as appropriate.

Full disclosure is part of the submission process.

Examples of competing interests

Financial

  • Paid employment or consultancy
  • Drugs in Context Editorial Board membership
  • Patent applications (pending or actual), including individual applications or those belonging to institutions to which authors/funders/reviewers/editors are affiliated and which those entities may benefit from
  • Research grants (from any source, restricted or unrestricted)

Nonfinancial

Nonfinancial competing interests include but are not limited to:

Professional

  • Acting as an expert witness
  • Membership in a government or other advisory board
  • Relationship (paid or unpaid) with organizations and funding bodies including nongovernmental organizations, research institutions or charities
  • Membership in lobbying or advocacy organizations
  • Writing or consulting for an educational company

Personal

  • Personal relationships with individuals involved in the submission or evaluation of a paper

Personal convictions (political, religious, ideological or other) related to a paper’s topic that may interfere with an unbiased publication process (at the stage of authorship, peer review, editorial decision making or publication)

Standards of reporting science – important sources of information

Drugs in Context recommends that peer reviewers and authors are familiar with the content made available at the following websites:

Authorship and contributorship

Drugs in Context recognises the differences between authors and contributors and fully adopts the new Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals published in August 2013 by the International Committee of Medical Journal Editors.

Appeal against editorial decisions

If any time during the editorial process the author wishes to appeal against editorial decisions, in the first instance please contact the Editor-in-Chief via the Editorial Office.

Suspected misconduct or disputed authorship

Drugs in Context uses the Committee of Publication Ethics flowcharts to deal with cases of suspected misconduct or disputed authorship.


DOES DRUGS IN CONTEXT ACCEPT ADVERTISING?

Yes, we would be happy to help if you wish to place an advertisement on our website. Please contact:
David Hughes
david.hughes@bioexcelpublishing.com


WHO SHALL I CONTACT ABOUT RIGHTS, REPRINTS AND PERMISSIONS?

David Hughes
david.hughes@bioexcelpublishing.com


WHERE IS DRUGS IN CONTEXT BASED?

Drugs in Context is an international journal published by BioExcel Publishing Limited which is a company registered in England (Number 10038393) with headquarters in the UK. The Editorial Board reflects the international scope of the journal and includes representatives from several countries.

Publisher address
Bioexcel Publishing Limited, Plaza Building, Lee High Road, London, SE13 5PT, UK

Change log
Updated: 11 August 2017, 26 July 2017, 02 July 2017, 08 February 2017, 23 December 2016, 30 November 2016, 31 October 2016, 29 June 2016, 10 September 2015, 12 May 2015, 22 April 2015, 27 October 2014

Resources